Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions (Q38021521)

27 August 2017

title

Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions (English)

1 reference

27 August 2017

1 reference

Gene H Barnett

1 reference

27 August 2017

Mital Patel

1 reference

27 August 2017

Michael A Vogelbaum

series ordinal

1 reference

27 August 2017

Rakesh Jalali

series ordinal

1 reference

27 August 2017

Manmeet S Ahluwalia

series ordinal

1 reference

27 August 2017

language of work or name

English

0 references

publication date

25 June 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

1247-1266

1 reference

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Molecularly targeted therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Therapeutic targeting of EGFR in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Progress on antiangiogenic therapy for patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Intussusceptive angiogenesis: its emergence, its characteristics, and its significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Tumour vascularization: sprouting angiogenesis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Activation of the HIF pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Notch signaling in glioblastoma: a developmental drug target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

VEGF Trap induces antiglioma effect at different stages of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Molecular mechanisms of glioma cell migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Inhibition of angiogenesis and invasion in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Integrins: the keys to unlocking angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Integrins: roles in cancer development and as treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Integrin alpha 6 regulates glioblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Synergistic antiglioma activity of radiotherapy and enzastaurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Pathway inhibition: emerging molecular targets for treating glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

γ-Secretase Inhibitors Enhance Temozolomide Treatment of Human Gliomas by Inhibiting Neurosphere Repopulation and Xenograft Recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Targeting cancer stem cells through L1CAM suppresses glioma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Convection-enhanced delivery of nanocarriers for the treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

Clinical trial end points for high-grade glioma: the evolving landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.703177

10.1517/13543784.2012.703177

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference